Medicinal Products

Nephrotect otopina za infuziju

Name Nephrotect otopina za infuziju
Marketing Authorisation Number HR-H-058269986
Active Substance izoleucin
leucin
lizinacetat
metionin
fenilalanin
treonin
triptofan
valin
arginin
histidin
alanin
acetilcistein
glicin
prolin
serin
tirozin
glicil-tirozin
Composition 1000 ml otopine za infuziju sadrži: 5,80 g izoleucina, 12,80 g leucina, 16,90 g lizin acetata (12,0 g lizina), 2,00 g metionina, 3,50 g fenilalanina, 8,20 g treonina, 3,00 g triptofana, 8,70 g valina, 8,20 g arginina, 9,80 g histidina, 6,20 g alanina, 0,54 g acetil cisteina (0,40 g cisteina), 5,31 g glicina, 3,00 g prolina, 7,60 g serina, 0,60 g tirozina i 3,16 g glicin-tirozina (0,994 g glicina i 2,40 g tirozina); ukupno 100 g/l aminokiselina, odnosno 16,3 g/l dušika
Pharmaceutical Form otopina za infuziju
Manufacturer Fresenius Kabi Austria GmbH, Graz, Austrija
Marketing Authorisation Holder Fresenius Kabi d.o.o., Radnička cesta 37a, Zagreb, Hrvatska
Marketing Authorisation Date 28.07.2020
MA Period of Validity unlimited
MA Revocation Date 09.06.2025*
Classification Number UP/I-530-09/17-02/717
Registration Number 381-12-01/154-20-04
Prescription Medicinal product subject to medical prescription
Type of prescription Medicinal product subject to restricted medical prescription
Distribution Supply through pharmacies (community)
Advertising to general public not allowed
ATC Code B05BA01
Marketing status Not marketed
SmPC download
PL download

*Note

Marketing authorisation has been revoked by request of the marketing authorisation holder. In accordance with Article 113 of Medicinal Products Act, only a medicinal product in respect of which a marketing authorisation has been granted by the Agency for Medicinal Products and Medical Devices or the European Commision, and a medicinal product in respect of which an authorisation for parallel import or parallel distribution has been granted may be placed on the market of the Republic of Croatia. By way of derogation from this provision, a batch of medicinal product may be on the market for no longer than 18 months following the expiry of revocation of the marketing authorisation, unless its shelf life expires first.

Packaging

Back